Alnylam Pharmaceuticals, Inc (ALNY)

Alnylam's stock price has been impacted by strong financial results, including a robust third quarter of 2025 with earnings per share (EPS) of $2.90 and total net product revenues reaching $851 million. Positive data from the Phase 3 HELIO-B study of vutrisiran in ATTR-CM led to a stock increase, reaching over $260 per share in June 2024 and further rising to over $450 following Amvuttra's approval in ATTR-CM. As of February 6, 2026, the closing price was $328.16. Analyst ratings are generally positive, with a consensus "Moderate Buy" rating and an average target price of $477.13 as of February 5, 2026. Institutional buying has been noted, although insider selling raised some short-term concerns in January 2026. Alnylam is expected to announce its Q4 2025 earnings on February 12, 2026.

Information directly detailing demand seasonality for Alnylam Pharmaceuticals' products and services is not explicitly available. Demand might be driven more by diagnosis rates and treatment initiation rather than typical seasonal fluctuations due to the company's focus on rare and genetically defined diseases.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics for genetically defined diseases. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam uses siRNA molecules to silence disease-causing genes. Its major commercialized products include ONPATTRO for hATTR amyloidosis with polyneuropathy, AMVUTTRA for hATTR amyloidosis with polyneuropathy and ATTR amyloidosis with cardiomyopathy, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia (partnered with Novartis AG). The company has a pipeline of investigational RNAi therapeutics across various therapeutic areas.

Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, U.S., and has a growing global presence with operations across North America, Europe, Asia, and South America. It maintains additional offices in locations such as Norton, Massachusetts, Maidenhead, U.K., Zug, Switzerland, Amsterdam, Netherlands, Tokyo, Japan, and Brazil. Alnylam's medicines are available in over 70 countries.

Alnylam Pharmaceuticals has maintained a positive brand reputation over the past year, being recognized as an exceptional workplace and a socially responsible organization. Alnylam has been named a "Best Workplace for Innovators" by Fast Company for five consecutive years. The company published its 2022 Corporate Responsibility Report, highlighting its commitment to advancing RNAi science and supporting health equity, meeting Diversity, Equity, and Inclusion (DE&I) goals, launching a formal U.S. supplier diversity program, and disclosing global multiyear data on its environmental impact.

Alnylam Pharmaceuticals, Inc. has significant institutional ownership, with 1361 institutional owners and shareholders holding a total of 152,180,502 shares, accounting for 87.77% of the company. Individual ownership stands at 0.43%. Major institutional shareholders include Fmr Llc, Capital World Investors, Vanguard Group Inc, BlackRock, Inc., Capital Research Global Investors, Jpmorgan Chase & Co, State Street Corp, Fidelity Management & Research Company LLC, BlackRock Institutional Trust Company, N.A., JP Morgan Asset Management, Baillie Gifford & Co., and Geode Capital Management, L.L.C.